The American Gastroenterological Association says the document is the first comprehensive, evidence-based guideline on the use of FMT for recurrent C difficile.
Treatment with the narrow-spectrum investigational antibiotic ridinilazole resulted in a 53% relative reduction of recurrent C difficile infection compared with vancomycin.
In a population-based study, patients recently exposed to antibiotics and proton pump inhibitors had an 18-fold increase in the risk of C diff infection.
A study of two large, integrated health systems found a high incidence of outpatient CDI, despite limited testing of patients with diarrhea.
Researchers say new cleaning and disinfection methods that can better eradicate C difficile spores could help reduce the risk of healthcare transmission.
The study also recovered C difficile spores from patient gowns and surgical scrubs, suggesting those items could be vectors for hospital transmission.
C diff infections cause roughly 30,000 US deaths each year.
Monoclonal antibodies and fecal microbiota-based products are changing the landscape for patients with recurrent Clostridioides difficile infection.
Clostridioides difficile infection is associated with elevated all-cause and cause-specific mortality.
Allowing bedside nurses to independently order testing for C difficile was tied to faster test results.